MedImmune helps Micromet develop MT103 for cancer; ends
- Drug Discovery Tools
- R+D and Marketing-Licensing
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.